Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Return on Sales (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Return on Sales for 6 consecutive years, with 15.05% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 3768.0% to 15.05% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 2.6% through Dec 2025, up 2978.0% year-over-year, with the annual reading at 2.6% for FY2025, 2985.0% up from the prior year.
  • Return on Sales hit 15.05% in Q4 2025 for Insight Molecular Diagnostics, up from 42.49% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 15.05% in Q4 2025 to a low of 120.3% in Q4 2022.
  • Historically, Return on Sales has averaged 33.72% across 5 years, with a median of 20.81% in 2024.
  • Biggest five-year swings in Return on Sales: skyrocketed 61664bps in 2021 and later plummeted -11035bps in 2022.
  • Year by year, Return on Sales stood at 9.94% in 2021, then tumbled by -1110bps to 120.3% in 2022, then surged by 98bps to 1.95% in 2023, then plummeted by -1062bps to 22.63% in 2024, then skyrocketed by 167bps to 15.05% in 2025.
  • Business Quant data shows Return on Sales for IMDX at 15.05% in Q4 2025, 42.49% in Q3 2025, and 19.0% in Q2 2025.